Registries that show efficacy: good, but not good enough.

[1]  D. Byar.  Why data bases should not replace randomized clinical trials. , 1980, Biometrics.

[2]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[3]  M. Aapro,et al.  Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Pritchard,et al.  A prospective study evaluating 18F-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer , 2008 .

[5]  Y. Ung,et al.  A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC) , 2008 .

[6]  D C Angus,et al.  Using large-scale databases to measure outcomes in critical care. , 1999, Critical care clinics.

[7]  Nicolette de Keizer,et al.  Model Formulation: Defining and Improving Data Quality in Medical Registries: A Literature Review, Case Study, and Generic Framework , 2002, J. Am. Medical Informatics Assoc..

[8]  B. Hankey,et al.  The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Mack.  Clinical trials versus registries in coronary revascularization: which are more relevant? , 2007, Current opinion in cardiology.

[10]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Coleman,et al.  The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development. , 2007, AJR. American journal of roentgenology.

[12]  L. Siminoff,et al.  Doctor-patient communication about breast cancer adjuvant therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Evidence-based medicine in anesthesiology. , 2001, Anesthesia and analgesia.

[14]  R. Coleman,et al.  The National Oncologic PET Registry (NOPR): Design and Analysis Plan , 2007, Journal of Nuclear Medicine.

[15]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[16]  A. Feinstein,et al.  The role of observational studies in the evaluation of therapy. , 1984, Statistics in medicine.

[17]  Angela Mariotto,et al.  Cost of care for elderly cancer patients in the United States. , 2008, Journal of the National Cancer Institute.

[18]  S. Larson.  Practice-based evidence of the beneficial impact of positron emission tomography in clinical oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Austin,et al.  Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding , 2005, BMJ : British Medical Journal.

[20]  S. Cannistra.  Gynecologic oncology or medical oncology: what's in a name? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Barry A Siegel,et al.  Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D C Angus,et al.  Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research. The Members of the Outcomes Research Workshop. , 1999, American journal of respiratory and critical care medicine.

[23]  D P Byar,et al.  Using observational data from registries to compare treatments: the fallacy of omnimetrics. , 1984, Statistics in medicine.

[24]  Elliott S Fisher,et al.  Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. , 2007, JAMA.

[25]  Deborah Schrag,et al.  Enhancing cancer registry data to promote rational health system design. , 2008, Journal of the National Cancer Institute.

[26]  Ping Li,et al.  Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding , 2005, BMJ : British Medical Journal.

[27]  Ralph B D'Agostino,et al.  Estimating treatment effects using observational data. , 2007, JAMA.